.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Merck
Daiichi Sankyo
Healthtrust
QuintilesIMS
Express Scripts
UBS
Covington

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,030,106

« Back to Dashboard

Which drugs does patent 7,030,106 protect, and when does it expire?


Patent 7,030,106 protects ZETIA and is included in one NDA. There has been one Paragraph IV challenge on Zetia.

Protection for ZETIA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has two hundred and thirty-three patent family members in thirty-eight countries.

Summary for Patent: 7,030,106

Title:Sterol absorption inhibitor compositions
Abstract:The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Inventor(s): Cho; Wing-Kee Philip (Princeton, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/136,968
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Msd Intl GmbhZETIAezetimibeTABLET;ORAL021445-001Oct 25, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,030,106

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,612,058Methods for inhibiting sterol absorption► Subscribe
6,541,640 Process for the preparation of 4-haloalkylnicotinonitriles► Subscribe
7,071,181Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors► Subscribe
7,053,080Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors► Subscribe
7,056,906Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women► Subscribe
6,982,251Substituted 2-azetidinones useful as hypocholesterolemic agents► Subscribe
6,864,385 Process for the preparation of 4-haloalkylnicotinonitriles► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,030,106

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina031658► Subscribe
Argentina032403► Subscribe
Argentina032643► Subscribe
Argentina033855► Subscribe
Argentina034204► Subscribe
Argentina035611► Subscribe
Argentina035739► Subscribe
Argentina064012► Subscribe
Argentina066143► Subscribe
Austria279425► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
AstraZeneca
US Army
Cerilliant
UBS
Merck
Argus Health
Dow
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot